Gerber Kawasaki Wealth & Investment Management Increases Stock Holdings in Eli Lilly and Company $LLY

Gerber Kawasaki Wealth & Investment Management boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 22.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,472 shares of the company’s stock after purchasing an additional 1,727 shares during the period. Gerber Kawasaki Wealth & Investment Management’s holdings in Eli Lilly and Company were worth $7,384,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of LLY. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter worth about $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $27,000. Financial Gravity Companies Inc. acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at $31,000. Bare Financial Services Inc increased its holdings in Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares during the last quarter. Finally, Blume Capital Management Inc. raised its stake in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Leerink Partnrs raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Finally, Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,087.32.

Eli Lilly and Company Stock Down 0.5%

Shares of NYSE LLY opened at $1,009.26 on Monday. The stock has a market capitalization of $954.13 billion, a price-to-earnings ratio of 49.38, a price-to-earnings-growth ratio of 1.12 and a beta of 0.37. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. The firm has a 50-day moving average price of $918.84 and a 200 day moving average price of $810.35. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period last year, the company posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.